Short answer: DSIP (delta sleep-inducing peptide, also called emideltide) was discovered in 1977 when Swiss researchers isolated a nine-amino-acid peptide from the blood of sleeping rabbits. Nearly 50 years later, it remains one of the least understood peptides on the market: its own receptor has never been identified, human sleep studies from the 1980s were small and inconsistent, and in July 2026 it was the only peptide an FDA advisory panel voted against making available for pharmacy compounding.
What DSIP is
DSIP is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Monnier and Schoenenberger reported in 1977 that infusing it into rabbits increased delta (deep, slow-wave) sleep. Since then it has been studied for sleep, stress, pain and withdrawal. Two basic facts remain unresolved: no specific DSIP receptor or gene has been identified, and it is not clear how a peptide this small and short-lived reaches the brain in meaningful amounts.
The human sleep studies
| What exists | What it found | Limits |
|---|---|---|
| Small studies in chronic insomnia (1980s) | Some reported improved sleep efficiency | Small samples, short duration, inconsistent results |
| Studies in healthy sleepers | Little or no consistent effect on deep sleep | Small |
| Withdrawal studies (opioids, alcohol) | Early positive reports | Uncontrolled or poorly controlled |
| Modern randomized trials | None | — |
Why the FDA panel said no
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides. It narrowly recommended allowing six of them (including BPC-157, TB-500 and Semax) for prescription compounding. Emideltide (DSIP) was the only one to receive a “no” vote. Even for a panel willing to loosen restrictions, the evidence for DSIP was too thin.
Side effects
The older human studies did not report serious toxicity, and reported effects were mild: headache, nausea, and in some reports daytime drowsiness or, paradoxically, disturbed sleep. These come from small studies decades ago. There is no modern safety data, and nothing on long-term or repeated use.
| Health Canada | Not authorized. DSIP is named in Health Canada’s April 2026 advisory on unauthorized injectable peptides. |
|---|---|
| FDA (USA) | Not approved; the July 2026 advisory panel voted against adding it to the compounding list. |
If sleep is the issue: cognitive behavioural therapy for insomnia (CBT-I) has far stronger evidence than any peptide. A doctor can help you access it.
See TrueLabs DSIP and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
What is DSIP?
DSIP (delta sleep-inducing peptide, or emideltide) is a nine-amino-acid peptide discovered in 1977 in the blood of sleeping rabbits, studied for its effects on deep sleep and stress.
Does DSIP work for sleep?
Small human studies from the 1980s gave inconsistent results, and no modern randomized trial exists. In 2026 an FDA advisory panel voted against making it available for compounding.
What are the side effects of DSIP?
Older studies reported mild effects such as headache, nausea and daytime drowsiness, with no serious toxicity, but modern safety data does not exist.
Why did the FDA panel reject DSIP?
DSIP was the only one of seven peptides reviewed in July 2026 to receive a vote against, reflecting the weakness of its evidence.
Is DSIP legal in Canada?
DSIP is not authorized by Health Canada and is named in its April 2026 advisory on unauthorized injectable peptides.
Related reading
References
- Monnier M, Schoenenberger GA, et al. Characterization of a sleep-inducing factor in rabbit blood. 1977. PubMed
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PubMed
- NPR. FDA panel considers easing peptide restrictions. July 23, 2026. NPR
- Health Canada. Think twice before injecting peptides bought online. April 9, 2026. Health Canada
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice.